
Opinion|Videos|December 30, 2024
Unmet Needs in Current IgAN Treatment
Key Takeaways
- Biomarkers, including genetic mutations and protein expressions, are vital for predicting disease progression and treatment response.
- Advanced diagnostic techniques are essential for identifying molecular and cellular indicators that inform patient prognosis.
Panelists discuss how the current treatment landscape for IgA nephropathy presents significant unmet needs, particularly in addressing the underlying causes of the disease and improving patient outcomes.
Advertisement
Episodes in this series

- What do you believe are the most significant unmet needs in the current treatment landscape for IgA nephropathy?
Advertisement
Advertisement
Advertisement
Trending on HCPLive
1
RAINIER: Povetacicept Cuts Proteinuria, Gd-IgA1 in IgA Nephropathy
2
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
3
Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD
4
IMAgINATION: Sefaxersen Meets Phase 3 Proteinuria Endpoint in IgA Nephropathy
5

